Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...

The Food and Drug Administration approved Merck's Keytruda in combination with Padcev to treat certain adults with muscle invasive bladder cancer (MIBC).

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the ...

Merck (MRK) stock is in focus as the FDA approves its Keytruda versions with Pfizer (PFE) and Astellas' (ALPMF) Padcev for ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The FDA approved enfortumab vedotin and pembrolizumab for MIBC, following a priority review of their sBLA for neoadjuvant and ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

With sales exceeding US$146 billion over the past decade, U.S. pharmaceutical giant Merck’s Keytruda has become the ...

The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv ...

The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer (MIBC).